



**Karolinska
Institutet**

Institutionen för biovetenskaper och näringslära

Molecular Characterization of Estrogen Receptor Beta Variants; Cancer Cell Proliferation and Invasion

AKADEMISK AVHANDLING

som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i Seminarierum Röd, plan6, NOVUM, Huddinge

Fredagen den 22 november, 2013, klockan 09.30

av

Li Xu

Huvudhandledare:

Professor Karin Dahlman-Wright
Karolinska Institutet
Institutionen för Biovetenskaper och
Näringslära

Bihandledare:

Docent Chunayan Zhao
Karolinska Institutet
Institutionen för Biovetenskaper och
Näringslära

Professor Jan-Åke Gustafsson
University of Houston
Center for Nuclear Receptors and Cell
Signaling

Fakultetsopponent:

Professor Jorma J. Palvimo
University of Eastern Finland
Institutionen för Biomedicine
Kuopio, Finland

Betygsnämnd:

Docent Svetlana Lagercrantz
Karolinska Institutet
Institutionen för Kliniskt verksam vid
Radiumhemmet

Docent Helena Berglund
Karolinska Institutet
Institutionen för medicinsk biokemi
och biofysik (MBB)

Docent Anders Isaksson
Uppsala University
Institutionen för Medicinal Sciences

Stockholm 2013

ABSTRACT

Estrogen plays crucial roles in the pathogenesis of breast cancer. Most of the known effects of estrogen signaling are mediated by estrogen receptors (ERs), ER α and ER β . ER α is explored for breast cancer molecular classification and is a target of endocrine therapy. The discovery of the second ER (ER β) including its variants led to a need for re-evaluation of the biology of estrogen. This thesis aims to characterize molecular aspects of ER β variants and provide knowledge to elucidate roles of ER β variants in tumorigenesis with focus on breast cancer.

In **PAPER I**, we determined the frequency of a novel human ER β isoform, human ER β 548 (hER β 548), which had been demonstrated to display different functional characteristics than wild-type ER β , in several populations including African (n = 96), Caucasian (n = 100), and Asian (n = 128) subjects. We did not detect any alleles that correspond to hER β 548 in these samples or in additional samples of heterogeneous origin. This study concluded, for the first time, that hER β 548 is not a common variant in Africans, Caucasians, or Asians.

In **PAPER II**, we identified five novel polymorphisms in the ER β gene in an African population. Two of these variants, I3V and V320G were expected to change the amino acid sequence of the ER β protein. Compared to the wild-type ER β , the V320G variant showed significantly decreased maximal transcriptional activity in the ERE mediated reporter assay. A pull-down assay and surface plasmon resonance analysis revealed that the decreased transcriptional activity of the novel ER β variant hER β V320G was associated with weaker interaction with a co-factor, TIF2.

In **PAPER III**, we assayed the interaction of several known ligands with mouse ER β 1 (mER β 1) and mouse ER β ins (mER β 2). A significant difference in ligand binding properties was observed. Our results suggest that ligand selectivity and co-activator recruitment of ER β isoforms constitute additional levels of specificity that influence the transcriptional response in estrogen target cells in mouse.

In **PAPER IV**, 202 clinical patient specimens, different non-small cell lung cancer (NSCLC) cell lines and transgenic mouse models were used to investigate the role of the EGFR signaling pathway for tumorigenesis of NSCLC. We showed that activation of the EGFR pathway or hypoxia could promote cell invasion but not survival. Furthermore, we demonstrated that the HIF-1 α /MET axis is involved in both EGFR and hypoxia induced signaling pathways, leading to cancer cell invasiveness.

In **PAPER V**, a breast cancer cell line BT549 that endogenously expresses the hER β variant hER β 2 in the absence of hER α and hER β was used to study the effects of hER β 2 signaling on breast cancer cell behavior and associated molecular mechanisms. Our data indicate that hER β 2 promotes proliferation and invasion in this cell line. A total of 263 genes were identified as hER β 2-upregulated genes and 662 identified as hER β 2-downregulated genes. hER β 2-regulated genes were involved in cell morphology, DNA replication and repair, cell death and survival. Based on our data, we hypothesize that effects of hER β 2 on proliferation and invasion were mediated via repression of prolyl hydroxylase 3 (PHD3) gene expression and induction of protein levels of the hypoxia induced factor 1 (HIF-1 α) and MET.

In conclusion, the studies presented in this thesis contribute to the knowledge of the function of ER β variants, and give additional insight into the molecular mechanisms underlying cancer cell proliferation and invasion.